Episodios

  • Joyce O’Shaughnessy, MD - Rising to the Challenges of Early and Advanced HR+ Breast Cancer: Examining Complex Evidence to Inform Clinical Decisions

    Joyce O’Shaughnessy, MD - Rising to the Challenges of Early and Advanced HR+ Breast Cancer: Examining Complex Evidence to Inform Clinical Decisions
    Jul 16 2024
    This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

    For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/BEX865. CME/MOC/NCPD/AAPA/IPCE credit will be available until July 2, 2025.

    Rising to the Challenges of Early and Advanced HR+ Breast Cancer: Examining Complex Evidence to Inform Clinical Decisions

    In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, Living Beyond Breast Cancer, and GRASP. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Support
    This activity is supported by independent educational grants from AstraZeneca, Genentech, a member of the Roche Group, and Lilly.

    Disclosure information is available at the beginning of the video presentation.

    Más Menos
    1 h y 25 m
  • Pier Luigi Zinzani, MD, PhD - Stepping Forward to Transform MCL Management: Guidance on the Selection and Use of BTKi Platforms as First-Line Therapy

    Pier Luigi Zinzani, MD, PhD - Stepping Forward to Transform MCL Management: Guidance on the Selection and Use of BTKi Platforms as First-Line Therapy
    Jul 16 2024
    This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

    For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/QHV865. CME/MOC credit will be available until July 17, 2025.

    Stepping Forward to Transform MCL Management: Guidance on the Selection and Use of BTKi Platforms as First-Line Therapy

    In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Support
    This activity is supported by an independent educational grant from AstraZeneca.

    Disclosure information is available at the beginning of the video presentation.

    Más Menos
    55 m
  • Paolo Ghia, MD, PhD - Opening With Innovation in CLL: The Practicalities and Potential of Finite Therapy With BTKi Platforms

    Paolo Ghia, MD, PhD - Opening With Innovation in CLL: The Practicalities and Potential of Finite Therapy With BTKi Platforms
    Jul 16 2024
    This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

    For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/UFU865. CME/MOC credit will be available until July 15, 2025.

    Opening With Innovation in CLL: The Practicalities and Potential of Finite Therapy With BTKi Platforms

    In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Support
    This activity is supported by an independent educational grant from AstraZeneca.

    Disclosure information is available at the beginning of the video presentation.

    Más Menos
    1 h y 13 m
  • Stephen V. Liu, MD - Decoding Biomarker Testing and Targeted Therapy in NSCLC: The Complete Guide for 2024

    Stephen V. Liu, MD - Decoding Biomarker Testing and Targeted Therapy in NSCLC: The Complete Guide for 2024
    Jul 16 2024
    This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

    For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/TFK865. CME/MOC/NCPD/AAPA/IPCE credit will be available until July 1, 2025.

    Decoding Biomarker Testing and Targeted Therapy in NSCLC: The Complete Guide for 2024

    In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Support
    This activity is supported through independent educational grants from AstraZeneca, Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies), Lilly, and Novartis Pharmaceuticals Corporation.

    Disclosure information is available at the beginning of the video presentation.

    Más Menos
    1 h y 25 m
  • Barbara Burtness, MD - Progress Meets Innovation in Head and Neck Cancer: Perspectives on Modern Immunotherapy and Novel Therapeutic Mechanisms

    Barbara Burtness, MD - Progress Meets Innovation in Head and Neck Cancer: Perspectives on Modern Immunotherapy and Novel Therapeutic Mechanisms
    Jul 3 2024
    This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

    For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NQB865. CME/MOC/NCPD/AAPA/IPCE credit will be available until July 1, 2025.

    Progress Meets Innovation in Head and Neck Cancer: Perspectives on Modern Immunotherapy and Novel Therapeutic Mechanisms

    In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Head and Neck Cancer Alliance. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Support
    This activity is supported by educational grants from AVEO Pharmaceuticals, Inc., Coherus BioSciences, Inc., and Merck & Co., Inc.

    Disclosure information is available at the beginning of the video presentation.

    Más Menos
    1 h y 26 m
  • Mansoor Raza Mirza, MD / Ana Oaknin, MD, PhD - Navigating Recent Advances in Endometrial Carcinoma Treatment: Expert Guidance to Unleash the Power of Immunotherapy and Other Emerging Therapeutic Regimens

    Mansoor Raza Mirza, MD / Ana Oaknin, MD, PhD - Navigating Recent Advances in Endometrial Carcinoma Treatment: Expert Guidance to Unleash the Power of Immunotherapy and Other Emerging Therapeutic Regimens
    Jul 3 2024
    This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

    For the full presentation, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/RZJ865. CME/MOC/NCPD/AAPA/IPCE credit will be available until June 27, 2025.

    Navigating Recent Advances in Endometrial Carcinoma Treatment: Expert Guidance to Unleash the Power of Immunotherapy and Other Emerging Therapeutic Regimens

    In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Support
    This educational activity is supported by an independent medical education grant from GSK.

    Disclosure information is available at the beginning of the video presentation.

    Más Menos
    50 m
  • Sundar Jagannath, MD, FASCO - Extending Innovation From Lymphoma to Myeloma: The Next Wave of Bispecific Antibody Breakthroughs for Clinical Care

    Sundar Jagannath, MD, FASCO - Extending Innovation From Lymphoma to Myeloma: The Next Wave of Bispecific Antibody Breakthroughs for Clinical Care
    Jul 3 2024
    This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

    For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/KQE865. CME/MOC/NCPD/AAPA/IPCE credit will be available until June 30, 2025.

    Extending Innovation From Lymphoma to Myeloma: The Next Wave of Bispecific Antibody Breakthroughs for Clinical Care

    In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Support
    This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

    Disclosure information is available at the beginning of the video presentation.

    Más Menos
    1 h y 28 m
  • Peter Voorhees, MD - Three Rs for Modern Myeloma Care: Delivering the Right Treatment for the Right Patient at the Right Time With Antibody and BCMA Platforms

    Peter Voorhees, MD - Three Rs for Modern Myeloma Care: Delivering the Right Treatment for the Right Patient at the Right Time With Antibody and BCMA Platforms
    Jul 3 2024
    This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

    For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VRK865. CME/MOC/AAPA/IPCE credit will be available until July 1, 2025 .

    Three Rs for Modern Myeloma Care: Delivering the Right Treatment for the Right Patient at the Right Time With Antibody and BCMA Platforms

    In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Support
    This activity is supported through educational grants from Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies), and Sanofi.

    Disclosure information is available at the beginning of the video presentation.

    Más Menos
    1 h y 53 m